Member Info for ratcliffewriter

Maybe the sleeping dogs should lie a bit less.

With respect, I don't think it's true to say 'The only reservation holding back some investors has been the scaremongering by a few naysayers suggesting a placing towards the end of the year.'

I think a lot of people with cash to invest have steered clear of this share for years, and as a consequence still have cash. Also, a poster pointing out cash burn v bank balance is hardly scaremongering, it's basic financial fact. Next, a look at the small and very stagnant pool of 'products' inspires no confidence at all, and the sustained track record of placings and consolidations has secured the destruction of many a hard earned few thousand, not to mention at least one life by all accounts.

'Talking it down to get in cheap' is a delusional line of thought. Look at the facts.

If you read what you've just posted you'll hear a loud rattling noise from a begging bowl.

Nothing is payable now - 'Payment of milestones in cash is subject to Ambrose raising capital in due course.'

In due course......that's nicely vague but should keep you in the hook for a few months at least.

If the news was actually good, solid and imminently promising, and the science was fresh, developing and compelling then ai could understand your enthusiasm, but having spent a long time looking at an investment case and the facts and data here, I suggest you do the same or at least don't just stick your fingers in your ears and shout 'la la la.'

Maybe you should actually read what you post - click on the 'people' tab on your link and you'll see the resignation is dated 1st June 2025, a female some 28 years younger than the sole remaining director of the same surname. So that's just 3 weeks since it was updated.

Anyway, where's the next money coming from to keep the coffin lid from slamming shut here?

I was just looking back at the history of 401 - it only had one peer review, and one of the reviewers was Suzy Dilly, so how much clout that carries I don't know, and the review is pretty shallow, mainly about safety tolerance and nothing I can see of significant clinical benefit being advanced.

Bear in mind also that the 401 trial involved very few patients and was carried out at a clinic at '6 Politkovskaya Street, Tbilisi 0186, Georgia', and the RNS telling of what results there are was released in November 2018 - coming up to seven years of silence on any clinical advancement, although to be fair PM2022 did tell me a while ago that Val doesn't do research any more, they are a lab company...

As far as the usual torrent at Porky9 by the way, it seems as unfair as usual because the much-trumpeted '16 million quid' is only subject to commercial and clinical milestones, and then presumably on something successful actually arising therefrom. So Porky's comments about a raise seem entirely likely - 401 has to be dusted off, defibrillated, manufactured, a clinic found, a series of patients recruited and treated, then monitored for some considerable time, results collated checked and published, and only assuming they are significantly successful could any reasonable financial inflow possibly occur. I can't see any great income even from clinical milestones, and at the most optimistic that has to be some 12 to 18 months away, so what is going to pay wages, lab costs, drug costs and so on, not to mention bonuses which must surely be due if this is such a good move for 401.

Looking at Companies House, where Ambrose Healthcare seems to have just the one director, the other (a relative judging by the name) resigned earlier this year, I can't see them dipping into their own pocket as it seems their capital a few months ago was just over 500 quid.

Why not wait and see if Porky's prediction of (another) raise comes about, or if not then say where you think a good many millions will be dug up from and needed well ahead of even the first possible clinical milestone?

Also can you imagine the gibbering if there was a random purchase by any BoD member -

'He hasn't bought many, obviously no faith in the company',

'He's bought a load, obviously insider information at work ahead of good news',

'He's bought a load, obviously insider information at work ahead of bad news',

'It's an act of desperation to pump the share, Vulpes want out',

'He's bought a load because nobody wants any',

'He's bought so many they must be unable to do a placing' etc etc -

I'm sure most here could write the script.

Best not to wake the children, they only start squawking and skriking.

Skidrow_inv - From your previous postings I suspect you bought into SCLP in the expectation of a reasonably quick buck on hoped-for timelines, ignoring the fact that any cutting edge process can suffer delays. How serious or how long they are is all part of the risk equation, and whether you think the light at the end of the tunnel will be dazzling or extinguished is something to assess when you decide how much, if any, money to put into a company.

Delay-wise, remember the problems getting the MOD1 vaccine into solution for administering? You probably don't, and maybe choose not to. That took months and months, but was overcome and is now history, but that's just one of many hurdles that have needed to be overcome before the development can move on. It's that kind of tenacity and problem-solving that gives a lot of investors here confidence in an ultimate success, but I fully appreciate the frustration and boredom generated by the same delays that result in unforeseen or unexpectedly more complex problems arising and needing resolution.

I would suspect that somehow your 'gamble' on Scancell has resulted in financial or personal problems - earache from the other half perhaps? Or a chronic need for extra funds which didn't materialise on the timescale you alone decided was immutable? Who knows, but throwing insults around as you do and oozing bitterness from every pore won't help you. Maybe a little less greed, a little more patience, and some balance to your investments wouldn't have left you as you are.

I'm surprised he's not had an early night as hes been doing a double shift today insulting others on the dark side too.

Very true point too Roses - 'It's a meaningless award, a put up job' versus 'It's a prestigious award and she didn't win it.' Usual mix and match to suit the agenda, very tiresome but probably unaware that it's a very very old hat technique.

You forgot to add IMO.

IMO.

You need to do a similar amount of in-depth trawling through the last few years' RNSs. You'd see far better where this company is(n't) going then.

As I predicted - 'A lot going on in the background....'

Sure there is....

I imagine the webinar will be full of things that are oh-so-nearly in reach, discussions that are hoped to take place, hints at things 'we can't go into detail at the moment' about, great interest in areas of the company 'which we hope will bear fruit in the near future, all stuff that sounds repetitively tempting but it just needs.....money. So with luck the pot can be stirred enough to create just a tiny bit of excitement to get the next placing away.

There may also be a bit about amazing cost savings which seem about as effective as funding a way of making the Titanic sink slower than it would otherwose have done, but no mention of bonuses. The lab will be talked up, but I bet there's no reference to the staff they've laid off because after a couple of years it's still nothing more than a net loss. If it hasn't started to draw in decent revenue in that time then I'd suggest it never will.

Then again, there may be a surprise in that Black Cat have finally come up with the 5 million they were going to rustle up, or some Cayman Islands fund will suddenly cough up 60 million in ready cash - oh but maybe that was TheoremRx, another amazing and protracted failure.

Pass the popcorn P9, there's a good chap.

And here's the link.

https://www.brrmedia.co.uk/broadcasts-embed/656f087285e1630925163743/valirx-plc/?popup=true

Interesting video from 18 months ago - have a watch of it, think how it sounded then, and compare it with what has actually come to fruition since with reference not just to Ambrose, but TheoremRx and 'Inaphea' as well.

That's certainly a post for the P9 haters to read and digest. 3 years on and it's worth 1.7 percent of its price at the time of posting.

'You might save a penny or two with a delay but at this price it is worth a strong buy.'

You might have saved a lot more by not buying at all - and that post was done when SD was in charge who he now vilified as a waste of space. So next time P9 or others post saying beware of ramping clubs with an agenda, be sure to take heed.

I suppose now it's a matter of buying on the dips, except a slope needs an upward tilt conform a dip, and that upward line is pretty elusive....

'..buying on the dips'

That would be funny if it hadn't cost so many people so much money. Look at the share graph over the past decade and more - it's basically a ski slope with the occasional spike which is where the 125:1 consolidations take place.

The whole share is essentially one sustained dip!

It's of little consequence where the apparent buys are from scinv, your disappointment shines through strongly regardless.

Thanks MP, but that's gone out of date already. A tick up. Nice to see and really not unexpected.

Correct that last to 'I doubt it would cause this subtle rise.'